Hydra Biosciences, Inc.

Development of molecular regeneration medicines, novel cardiovascular therapies and drugs targeting novel ion channels as as an alternative to cell-based therapies for organ and tissue restoration.

Hydra Biosciences was founded in 2001 by Laurie Bartlett Keating, David Clapham, Mark Keating and Dean Li. Hydra Biosciences has secured $9.3 million in Series A funding and $18.875 million in Series B funding. Sophion and Hydra established a reference site for the QPatch Automated Patch Clamp System

Russell Herndon, President, CEO
Glenn Larsen, PhD, CSO, Executive VP of Research and Development
Tom Burke, VP of Finance and Treasurer

Robert Carpenter, Chairman
Russell Herndon
Michael Bigham
Darren Carroll
Laurie Bartlett Keating
Glenn Larsen, Ph.D.
Amir Nashat, Ph.D.
Hugh Rienhoff, M.D.

David Clapham, PhD, MD
Mark Keating, MD
Dean Li, PhD, MD
Garbers David, PhD
David Julius, PhD
Eric Olson, PhD
Michael Sanguinetti, PhD

790 Memorial Drive
Cambridge, MA 02139
USA
Phone: +1-617-494-5230
Fax: +1-617-494-5245

The company’s approach to regeneration is based on cell dedifferentiation: Dedifferentiation assays, genetics, genomics and signal transduction technologies help Hydra to discover proteins and small molecules that are able to reprogram a patient’s own mature cells within the patient’s own body. Damaged or destroyed cells can thus be replaced. Commercial applications for Hydra’s molecular regeneration medicines include diseases of the heart, vasculature, retina, central nervous system, pancreas, skin and joints.